Amyloidosis is a disease that results from the accumulation of a toxic, insoluble protein called amyloid in various tissues and organs, which eventually leads to organ failure. Amyloidosis can be acquired or hereditary, and occurs when protein misfolding turns soluble precursor proteins into insoluble fibrils. There are four main types of amyloidosis: light chain (AL) amyloidosis, AA amyloidosis, ATTR amyloidosis, and AB2M amyloidosis. Amyloidosis remains a challenging disease to diagnose and treat, although recent advances and data from clinical trials provide promising future therapeutic strategies.

In this exclusive podcast, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Maria Moscvin, MD, Brigham and Women’s Hospital, Boston, MA, discuss treatment approaches and clinical trial updates to bring you the latest in this field. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.

The post Recent advances in amyloidosis treatment appeared first on VJHemOnc.